A study sought to examine the epidemiology, clinical presentation, and treatment outcomes of multidrug-resistant or rifampicin-resistant tuberculosis (MDR/RR-TB) in Morobe Province, Papua New Guinea (PNG), while also evaluating the impact of the COVID-19 pandemic on case detection and treatment outcomes during 2020 and 2021. To achieve this, researchers conducted a retrospective descriptive and analytic review of programmatic data collected over a 10-year period, from 2012 to 2021. The population studied included all individuals diagnosed with MDR/RR-TB in Morobe Province who initiated treatment within this timeframe.
The findings revealed that MDR/RR-TB case notifications in Morobe were stable from 2012 to 2015 but showed a steady increase until peaking at 42 cases in 2020. This rise was followed by a notable decline in 2021, coinciding with the major disruptions brought on by the COVID-19 pandemic. In terms of demographics, the median age of individuals diagnosed was 33 years, with the largest age group being those aged 25 to 34. Most cases occurred among males and urban residents, while children under 15 years made up only a small proportion (2.5%).
Clinically, nearly all identified cases were pulmonary TB, with only one extrapulmonary TB case reported. The HIV co-infection rate was low at 4%; however, the HIV status was unknown in 42% of patients, indicating a significant data gap. Over the study period, treatment outcomes improved substantially. The rate of unfavourable outcomes dropped from 91% in 2014 to 22% in 2019, before increasing again during the pandemic years—rising to 24% in 2020 and 29% in 2021. These reversals highlight the adverse effects of the pandemic on TB service delivery and patient care.
A key finding was the improved success associated with shorter, all-oral treatment regimens lasting 9 to 11 months. Patients on these regimens had a 73.7% favourable outcome rate, compared to 45.8% among those on longer, injectable-based regimens. Statistical analysis identified male sex and treatment with longer injectable regimens as significant risk factors for unfavourable outcomes. Overall, the study underscored the effectiveness and better tolerability of shorter, all-oral regimens, while also emphasizing the urgent need for enhanced case finding, diagnostic capabilities, and decentralization of TB services in Morobe Province.
Source: Bumbu, L., Vaccher, S., Holmes, A., Sodeng, K., Graham, S.M. and Lin, Y.D., 2024. Drug-resistant TB in Morobe Province, Papua New Guinea, 2012–2021. Public Health Action, 14(4), pp.146-151.
No comments:
Post a Comment